Abstract
The objective of this article was evaluate the use of flibanserin in comparison to the placebo in increasing sexual desire in women pre menopausing. A systematic review protocol was done by means of a research in the data basis Cochrane, Pubmed and BVSaúde. The papers were selected by two independent revisors, considering pre-definite inclusion and exclusion criteria. This systematic review contains 8 randomized clinical trials, derived from 474 articles. The studies analyzed the capacity of flibanserin to increase libido in patients diagnosed with hypoactive sexual desire, excluding other causes. The outcome demonstrated efficacy of the drug when administrated in a dosage between 50 mg and 100mg, during at least 24 weeks, despite all the side effects. It is possible to conclude that use of flibanserin in the treatment of post menopause women with hypoactive sexual desire, compared to the placebo, was efficient, if used for a minimum of 24 weeks, in the dosage between 50 mg and 100 mg.